SMARCA2 TR-FRET Assay Kit
The SMARCA2 TR-FRET Assay Kit is designed to measure the inhibition of SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 2) binding to its substrate in a homogeneous 384-reaction format. This FRET (Time Resolved Fluorescence Resonance Energy Transfer)-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward: a terbium-labeled donor, dye-labeled acceptor, SMARCA2 protein (amino acids 1375-1511), Bromodomain Ligand, and test inhibitor are incubated together for 120 minutes. Then, the fluorescence intensity is measured using a fluorescence reader capable of measuring TR-FRET.
Need us to run inhibitor screens or profile your compounds against SMARCA2? Check out our Bromodomain Screening Services.
- Fluorescent reader capable of measuring Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
- Adjustable micropipettor and tips
Catalog # | Name | Amount | Storage |
31141 | SMARCA2, GST-Tag* | 10 µg | -80°C |
33003 | Bromodomain Ligand 2 | 1 µg | -80°C |
Tb-Labeled Donor | 2 x 10 µl | -20°C | |
Dye-Labeled Acceptor | 2 x 10 µl | -20°C | |
33012 | 3x BRD TR-FRET Assay Buffer 1 | 4 ml | -20°C |
79969 | White, Nonbinding, low volume, microtiter plate | 1 | Room temp. |
*The concentrations of protein are lot-specific and will be indicated on the tubes containing the protein.
SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 2), also known as SNF2L2 has helicase and ATPase activity and is part of the SNF/SWI (Switch/Sucrose Non-Fermentable) ATP-dependent chromatin remodeling complex. SMARCA2 is a multidomain protein. One its domains, the BRD (bromodomain) binds to acetylated lysine in histone tails. Mutations in SWI/SNF protein accounts for about 20% of tumors. Interestingly, in cancers involving SMARCA4 mutations, inactivation of SMARCA2 results in synthetic lethality. The use of inhibitors could thus be of interest, however so far, most inhibitors have dual specificity for both SMARCA2 and SMARCA4 and have dose-limiting tolerability issues. Few inhibitors are also targeting the BRD domain, the main one being PIF3. One alternative approach is the development of PROTACs (proteolysis targeting chimeras). Further studies on this protein and continued development of strategies to target it will open new doors in cancer treatment.
Schiaffino-Ortega S., et al., 2014. J. Hematol. Oncol. 7:81.
Lu T., et al., 2018 Acta Pharmacologica Sinica 39:1544-1552.
Cantley J., et al., 2022 Nature Communications 13:6814.